Oral Cancer News – Page 305

Row erupts over oral cancer paper authorship

Source:The Australian Writer: Gay Healy AN international expert on oral cancer withdrew from joint authorship of a paper that drew a link between the disease and theListerine mouthwash made by his university laboratory's corporate sponsors, it has been claimed. The research paper's co-authors say Newell Johnson, whose Griffith University laboratory was funded by pharmaceutical firm Pfizer, Listerine's recent owner, decided not to put his name to the research paper, which made headlines across the world with its finding that alcohol-based mouthwashes were implicated in oral cancer. Professor Johnson says he was never an author. The claim about his involvement and withdrawal, made by Australian co-authors Michael McCullough of the University of Melbourne and Camile Farah of the University of Queensland, adds a new dimension to the controversy ignited by the paper, published in the Australian Dental Journal last December. In January UQ's head of dentistry Laurence Walsh came to the defence of mouthwashes, arguing they might prevent oral cancer, but later conceded that Listerine's present owner, Johnson & Johnson, had sponsored some of his workshops. The paper found the risk of oral cancer was increased by prolonged use of alcohol-based mouthwashes and highlighted six Listerine products. Professor McCullough said the research paper or literature review sprang from a 2007 meeting of the three researchers at a conference in Amsterdam. "After a session on the role of alcohol in oral cancer, we ended up deciding that we would formally write this article and review it between the three of us," hesaid. [...]

Webmaster2009-02-17T12:18:31-07:00February, 2009|Oral Cancer News|

Dental Calamities That Can Truly Hurt

Source: New York Times Writer: Nicholas Bakalar DENTAL cavities are not good news, but when it comes to preventive oral health, they may be among the smaller problems. The advice is familiar: brush and floss regularly, use fluoride mouthwash, limit snacks and sweet drinks, visit the dentist twice a year. Good suggestions, even if not everyone follows them: by age 12, 50 percent of children have cavities. But there are two much more serious problems, common dental diseases that can lead not only to loss of teeth but also to loss of life: periodontal disease and oral cancer. Periodontal disease — a chronic bacterial infection of the gums that destroys the bone and tissues that hold the teeth — is the leading cause of tooth loss in adults. Some people are genetically susceptible, and the problem can be aggravated by smoking, taking certain medications, stress and other factors. Several studies have found that gum disease is associated with an increased risk for heart attack. “It isn’t nailed down yet,” said Dr. Martin J. Davis, professor of clinical dentistryat the College of Dental Medicine at Columbia, “but there seems to be a link between the inflammation of gums and the inflammatory markers of heart disease.” It may be that oral bacteria enter the bloodstream, attach to fatty plaques in the coronary arteries and cause clots to form. Or maybe inflammation itself increases plaque buildup. A 2007 study showed that periodontal disease increased the risk of heart disease in men by one third and doubled it in women, even [...]

Webmaster2009-02-17T09:56:09-07:00February, 2009|Oral Cancer News|

Smokeless tobacco may not help smokers quit

Source: health.usnews.com Author: staff Cultural factors appear to influence whether smokeless tobacco can help smokers quit cigarettes, contends a new study. In Sweden, many smokers try to quit smoking by using snus, a form of moist, powdered tobacco that's placed under the lip. In Sweden, snus is more popular among male smokers, and Swedish men have higher smoking cessation rates than women. Some people have suggested that public health officials in the United States and other countries should promote smokeless tobacco as a way to help smokers quit cigarettes. However, University of California, San Diego, researchers examined data collected from more than 15,000 people in the United States and found that smokeless tobacco does not increase American smokers' quit rates. "With an ongoing tobacco control effort, men in the U.S. seem to be quitting smoking at higher rates than men in Sweden. And U.S. women are quitting at the same rate, unlike their counterparts in Sweden," study author Shu-Hong Zhu, a professor of family and preventive medicine in the UCSD School of Medicine, said in a university news release. The study found that: Among American men, less than 1 percent of current smokers switched to smokeless tobacco during the 12-month study. Only 1.7 percent of former smokers turned to smokeless tobacco. Men's quit rate for smokeless tobacco was three times higher than for cigarettes. Men were far more likely than women to use smokeless tobacco products, but smoking cessation rates were similar among men (11.7 percent) and women (12.4 percent). [...]

Oral Cancer Foundation News Team - A2009-04-07T18:24:34-07:00February, 2009|Oral Cancer News|

Visual Screening for Oral Cancer is Cost Effective in Low-Income Countries

Source: Carolina News Wire Writer: Lisa Bistreich, Patrick Gibbons RESEARCH TRIANGLE PARK, N.C. — Using visual inspection to screen for oral cancer is a cost-effective approach to earlier diagnosis in low- and middle-income countries, according to a study conducted by researchers at RTI International. The study, published in the Bulletin of the World Health Organization, looked at health care workers in Southern India, where oral cancer is a major health problem, and found that visual oral screening, particularly among high-risk individuals is cost-effective. "Our results show that screening for oral cancers by visual inspection is comparable or less expensive than the more widely accepted practice of screening for cervical cancers," said lead author Sujha Subramanian, a senior health economist at RTI. "We hope that the findings of this study will increase screening for oral cancers and help reduce the devastating impact of this cancer on families." More than 160,000 people participated in the study, and the researchers found that targeted screening of the high-risk group of alcohol and tobacco users is the most cost-effective approach. They determined that visual inspection for oral cancer targeted to high-risk people could be performed for under $6 per person over the course of a nine-year screening program. According to GLOBOCAN, the Indian subcontinent alone accounts for one-third of the world burden and oral cancer is the most common form of cancer and cancer-related death among men in India. Two-thirds of all deaths from oral cancers occur in low income countries. Worldwide, 270,000 new cases and 145,000 [...]

Webmaster2009-02-12T16:14:33-07:00February, 2009|Oral Cancer News|

Gwyneth Paltrow: Charity Chick

Source: Gossipgirls.com She’s always been interested in using her celebrity for the benefit of others, and last night Gwyneth Paltrow was spotted at the Women’s Cancer Research Fund’s ‘Unforgettable Evening.’ The “Shakespeare in Love” hottie was looking absolutely gorgeous as she arrived at the Beverly Wilshire Hotel, sporting a white dress with a matching blazer and a pair of pink and yellow feathered heels as she mingled with guests including Courtney Cox and Rita Wilson. And Gwyn was more than just another attendee at the event - she also received the 2009 Courage Award for her dedication to cancer research. Gwyneth, along with her mother Blythe Danner and brother Jake Paltrow founded the Bruce Paltrow Oral Cancer Fund in memory of her father who suffered for years with mouth cancer, and finally lost his battle in 2002. The fund is part of the National non-profit Oral Cancer Foundation, (http://www.oralcancer.org)

Webmaster2009-02-13T00:43:23-07:00February, 2009|Oral Cancer News|

Gwyneth Paltrow & More At Cancer Benefit Tuesday In LA

Source: LA News Reporter: Access Hollywood Tonight in LA for a cancer benefit, honorees Gwyneth Paltrow and Courteney Cox will join Jennifer Aniston, David Arquette, Sheryl Crow, Lisa Kudrow, Laura Dern, Jennifer Meyer and Tobey Maguire, Angie Harmon and Jason Sehorn, Josh Groban, Lisa Rinna and Harry Hamlin, Kirk and Anne Douglas, Jessica Capshaw, along with the Entertainment Industry Foundation’s (EIF’s) Women’s Cancer Research Fund (WCRF) honorary chairs Rita Wilson and Tom Hanks, and Kate Capshaw and Steven Spielberg. Also attending are EIF’s WCRF co-founders Kelly Chapman Meyer, Jamie Tisch, Anne Douglas, Quinn Ezralow, Marion Laurie, and Saks Fifth Avenue Beverly Hills’ Vice President & General Manager Larry Bruce. The event, at the Beverly Wilshire Hotel in Beverly Hills, will feature a performance by Beyonce. The 14th Annual Saks Fifth Avenue’s Unforgettable Evening benefiting the Entertainment Industry Foundation’s Women’s Cancer Research Fund (EIF’s WCRF), raises much needed funds each year for innovative cancer research, and recognizes one remarkable individual for his or her unwavering commitment to the cause. Oscar winner Gwyneth Paltrow will receive the 2009 Courage Award. She, along with her mother, Blythe Danner, and brother, Jake Paltrow, established the Bruce Paltrow Fund in memory of her father who lived with oral cancer for several years. The Bruce Paltrow Fund, set up through The Oral Cancer Foundation and with support from the EIF, works to prevent oral cancer through public education, early detection and patient support. In 2008, Paltrow served as ambassador for EIF and Saks Fifth Avenue’s KEY TO THE CURE Initiative, appearing in a [...]

Webmaster2009-02-11T14:09:48-07:00February, 2009|Oral Cancer News|

Risk of cerebrovascular events after neck and supraclavicular radiotherapy: a systematic review

Source: Radiother Oncol, January 24, 2009 Author: Apryl S Scott, Luke A Parr, and Peter A S Johnstone Objective: Although low dose radiation therapy (RT) has been used to prevent re-occlusion of coronary arteries, it may also precipitate vascular damage. Specifically, irradiation to the neck is related to subsequent vascular wall thickening and atherosclerotic plaque formation. Several investigators, reporting patients with varied disease processes and using different methods, have described an increased risk of cerebrovascular events (CVEs) after RT to the neck for head and neck cancer, breast cancer, or lymphoma. Our purpose is to determine the rate and risk of CVEs in patients after receiving radiation therapy to the neck. Methods: We performed a pooled analysis of the published data to document the cumulative risk of subsequent stroke after RT to the neck. An extensive MEDLINE and PUBMED search yielded five articles involving 6908 patients describing institutional series or cohort analyses comparing the frequency of CVE in irradiated versus non-irradiated patients. Results: Sixty-six CVEs were reported in 2567 patients after neck RT, whereas only 12 CVEs were documented in 4119 non-irradiated patients. Crude risk of CVEs after neck RT was 2.6%, and was 0.29% in non-irradiated patients. This odds ratio of 9.0 was statistically significant (95% CI 4.9, 16.7; p<0.0001). Data for supraclavicular RT were more difficult to analyze given differences in populations and reporting between the three studies, but it appears a significant risk is unlikely. Conclusions: Neck RT increases the likelihood of CVEs, but this risk must [...]

Oral Cancer Foundation News Team - A2009-02-11T12:38:25-07:00February, 2009|Oral Cancer News|

USC study finds that green tea blocks benefits of cancer drug

Source: news.biocompare.com Author: staff Contrary to popular assumptions about the health benefits of green tea, researchers at the University of Southern California (USC) have found that the widely used supplement renders a cancer drug used to treat multiple myeloma and mantle cell lymphoma completely ineffective in treating cancer. The study, which found that a component of green tea extract (GTE) called EGCG destroys any anticancer activity of the drug Velcade in tumor-bearing mice, will be published in a future print edition of the journal, Blood. It is now available online at the journal's pre-publication First Edition website. "Our finding that GTE or EGCG blocked the therapeutic action of Velcade was completely unexpected," says lead author Axel H. Schönthal, PhD, associate professor in the Department of Microbiology and Immunology at the Keck School of Medicine of USC. "Our hypothesis was that GTE or EGCG would enhance the anti-tumor effects of Velcade, and that a combination of GTE with Velcade (or EGCG with Velcade) would turn out to be a superior cancer treatment as compared to treatment with Velcade alone." Herbal remedies, including green tea, have become a popular remedy for cancer patients dealing with side effects of chemotherapy. However, these supplements are unregulated and, for most, their beneficial and/or detrimental effects have not been qualified through research. Using preclinical models and tumor-bearing mice, the researchers found that the unusually effective blockage of Velcade's therapeutic activity was based on the chemical interaction between molecules. The EGCG molecule and the Velcade molecule were [...]

Oral Cancer Foundation News Team - A2009-02-10T13:47:46-07:00February, 2009|Oral Cancer News|

Perceptronix reports clinical study underway to evaluate OralAdvance(TM) for early detection of oral cancer

Source: www.earthtimes.org Author: press release Perceptronix Medical Inc. announces that a clinical study of OralAdvance(TM), a test for the early detection of oral cancer, is now underway. The clinical study will assess the performance of OralAdvance(TM) compared to the gold standard biopsy and histology for its ability to differentiate between visually suspicious oral lesions with cancer or pre-cancer and visually suspicious benign oral lesions. "Unlike many other types of cancer, the incidence and mortality rates of oral cancer have not shown significant improvement over the past 30 years. By the time most oral cancers are diagnosed, they are already symptomatic late-stage disease. At Perceptronix we are dedicated to changing this paradigm towards early detection for better patient outcomes," says Dr. Bojana Turic, President and CEO of Perceptronix. Patients for the blinded study will be recruited from the BC Cancer Agency's Vancouver and Fraser Valley Centres. "We are pleased to be able to participate in the evaluation of the test in a clinical setting with technology that was developed in partnership with scientists at the BC Cancer Agency's Research Centre, and we are hopeful that the test will have a positive impact on the early detection of oral cancer," says Dr. Allan Hovan (Provincial Professional Practice Leader, Program in Oral Oncology/Dentistry, BC Cancer Agency). Currently, the death rate for oral cancer is higher than that of cervical cancer, Hodgkin's disease, cancer of the brain, liver, testes, kidney, or malignant melanoma. High death rate associated with oral cancer could be reduced significantly [...]

Oral Cancer Foundation News Team - A2009-02-09T16:56:36-07:00February, 2009|Oral Cancer News|

Gene study finds link to cancer of thyroid

Source: nytimes.com Author: Nicholas Wade Scientists have identified two genetic variations that account for 57 percent of cases of thyroid cancer, a finding that could lead to earlier detection among people at high risk for the disease. The report, from the Icelandic company Decode Genetics, may also lead to a resurgence of interest in the quest for the genetic roots of other common maladies like heart disease and schizophrenia. Genetic variants for many such diseases have been identified, but most have turned out to account for a disappointingly small percentage of cases. A scientific team led by Julius Gudmundsson of Decode Genetics reported Friday in the journal Nature Genetics that the two variants each lie at a site on the human genome near genes that control development of the thyroid gland. The variants are changes in a single chemical unit of the genome, which is some three billion units in length. Compared with people who have neither variant, “the risk associated with these variants was almost sixfold, which is quite extraordinary,” said Dr. Erich M. Sturgis, a head and neck surgeon at the M. D. Anderson Cancer Center in Houston who was not connected with the research. Dr. James A. Fagin, chief of endocrinology at the Memorial Sloan-Kettering Cancer Center in New York, said the new study was a significant advance, noting that the Decode Genetics scientists had bolstered their results by replicating the findings among Icelanders in two other populations of European descent, in Columbus, Ohio, and in Spain. [...]

Oral Cancer Foundation News Team - A2009-02-08T18:21:44-07:00February, 2009|Oral Cancer News|